



News Release

Source: Patheon Inc.
Website: www.patheon.com

Patheon's Puerto Rico Site Receives European Regulatory Approval

RESEARCH TRIANGLE PARK, North Carolina, (August 10, 2009) Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that its Manati, Puerto Rico solid dose manufacturing facility received regulatory approval from the European Medicines Agency (EMA) following the completion of a successful inspection in May by the Medical Products Agency of Sweden.

The successful inspection of the Manati facility demonstrates Patheon's strong commitment to quality and regulatory compliance. So far in 2009, Patheon has successfully completed 19 regulatory inspections at 9 manufacturing sites, including 8 FDA inspections and 2 European inspections. "Patheon's track record of regulatory compliance underscores our commitment to quality and reliability for our customers. We are particularly pleased with this recent result in Puerto Rico, as it represents the latest in a successful number of recent inspections," says Terry Novak, President, Patheon North America. "The approval of our Manati facility allows us to ship solid dosage product into Europe from Puerto Rico, which provides additional benefit and flexibility for our clients."

About Patheon Inc.

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through the commercial manufacturing of a wide array of dosage forms including parenteral, solid, semi-solid and liquids. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical supplies, scale-up and commercialization. Patheon's ability to integrate development and manufacturing services ensures that our customers' projects are delivered on time and meet the high standards of quality that Patheon is known for.

Patheon's integrated development and manufacturing network of 10 facilities and 7 development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

Contacts:

Mr. Wes Wheeler
President & Chief Executive Officer
Tel: (919) 226-3200
Email: wes.wheeler@patheon.com

Mr. Eric Evans
Chief Financial Officer
Tel: (919) 226-3200
Email: eric.evans@patheon.com